Efficacy and safety of adalimumab in patients with psoriasis previously treated with anti‐tumour necrosis factor agents: subanalysis of BELIEVE

Background  Few large clinical studies have evaluated whether switching tumour necrosis factor antagonists (anti‐TNFs) is likely to improve psoriasis in patients with prior anti‐TNF treatment.

[1]  J. Saurat,et al.  A phase IIIb, multicentre, randomized, double‐blind, vehicle‐controlled study of the efficacy and safety of adalimumab with and without calcipotriol/betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE study , 2010, The British journal of dermatology.

[2]  R. Bissonnette,et al.  Efficacy and safety of adalimumab in patients with plaque psoriasis who have shown an unsatisfactory response to etanercept. , 2010, Journal of the American Academy of Dermatology.

[3]  J. Barker,et al.  Adalimumab for psoriasis patients who are non‐responders to etanercept: open‐label prospective evaluation , 2009, Journal of the European Academy of Dermatology and Venereology : JEADV.

[4]  L. Naldi,et al.  European S3‐Guidelines on the systemic treatment of psoriasis vulgaris , 2009, Journal of the European Academy of Dermatology and Venereology : JEADV.

[5]  Frank O. Nestle,et al.  Mechanisms of Disease: Psoriasis. , 2009 .

[6]  P. Yamauchi,et al.  Adalimumab treats psoriasis in patients previously treated with etanercept: a case series. , 2009, Journal of the American Academy of Dermatology.

[7]  E. Sasso,et al.  Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. , 2009, Clinical immunology.

[8]  C. De Simone,et al.  Influence of body mass index, comorbidities and prior systemic therapies on the response of psoriasis to adalimumab: an exploratory analysis from the APHRODITE data. , 2008, Journal of biological regulators and homeostatic agents.

[9]  Sapna Modi,et al.  Sustained efficacy and safety of adalimumab in psoriasis treatment: a retrospective study of 49 patients with and without a history of TNF-alpha antagonist treatment. , 2008, Archives of dermatology.

[10]  Steven R Feldman,et al.  Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. , 2008, Journal of the American Academy of Dermatology.

[11]  J. Sánchez-Carazo,et al.  Efficacy of Etanercept in Psoriatic Patients Previously Treated with Infliximab , 2008, Dermatology.

[12]  J. Saurat,et al.  Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION) , 2007, The British journal of dermatology.

[13]  G. D'Haens,et al.  Adalimumab Induction Therapy for Crohn Disease Previously Treated with Infliximab: A Randomized Trial , 2008 .

[14]  B. Strober,et al.  Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. , 2008, Journal of the American Academy of Dermatology.

[15]  S. Chimenti,et al.  Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics. , 2007, Journal of the American Academy of Dermatology.

[16]  R. Kalb,et al.  Infliximab in the treatment of psoriasis in patients previously treated with etanercept. , 2007, Journal of the American Academy of Dermatology.

[17]  P Geusens,et al.  Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice. , 2007, Rheumatology.